{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:38:39Z","timestamp":1793824719512,"version":"4.6.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rare diseases pose immense challenges for healthcare systems due to their low prevalence, associated disabilities, and attendant treatment costs. Advancements in gene therapy, such as treatments for Spinal Muscular Atrophy (SMA), have introduced novel therapeutic options, but the high costs, exemplified by Zolgensma\u00ae at US$2.1\u00a0million, present significant financial barriers. This scoping review aimed to compare the funding approaches for rare disease treatments across high-performing health systems in Australia, Singapore, South Korea, the United Kingdom (UK), and the United States (US), aiming to identify best practices and areas for future research.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In accordance with the PRISMA-ScR guidelines and the methodological framework by Arksey and O\u2019Malley and ensuing recommendations, a comprehensive search of electronic databases (Medline, EMBASE, and Cochrane) and grey literature from health department websites and leading national organizations dedicated to rare diseases in these countries was conducted. Countries selected for comparison were high-income countries with advanced economies and high-performing health systems: Australia, Singapore, South Korea, the UK, and the US. The inclusion criteria focused on studies detailing drug approval processes, reimbursement decisions and funding mechanisms, and published from 2010 to 2024.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Based on a thorough review of 18 published papers and grey literature, various strategies are employed by countries to balance budgetary constraints and access to rare disease treatments. Australia utilizes the Life Saving Drugs Program and risk-sharing agreements. Singapore depends on the Rare Disease Fund, which matches public donations. South Korea\u2019s National Health Insurance Service covers specific orphan drugs through risk-sharing agreements. The UK relies on the National Institute for Health and Care Excellence (NICE) to evaluate treatments for cost-effectiveness, supported by the Innovative Medicines Fund. In the US, a combination of federal and state programs, private insurance and non-profit support is used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Outcome-based risk-sharing agreements present a practical solution for managing the financial strain of costly treatments. These agreements tie payment to actual treatment efficacy, thereby distributing financial risk and promoting ongoing data collection. Countries should consider adopting and expanding these agreements to balance immediate expenses with long-term benefits, ultimately ensuring equitable access to crucial treatments for patients afflicted by rare diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13561-024-00519-1","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T09:01:54Z","timestamp":1718787714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review"],"prefix":"10.1186","volume":"14","author":[{"given":"Qin Xiang","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai En","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Sheng Khai","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Jia Xuan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansel Shao Pin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwei Wuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald Choon Huat","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"issue":"6","key":"519_CR1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","volume":"18","author":"T Richter","year":"2015","unstructured":"Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA, International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Group. Rare disease terminology and Definitions-A systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18(6):906\u201314. https:\/\/doi.org\/10.1016\/j.jval.2015.05.008.","journal-title":"Value Health"},{"key":"519_CR2","unstructured":"KK Women\u2019s and Children\u2019s Hospital. Rare Disease Fund. KK Women\u2019s and Children\u2019s Hospital. 2023. https:\/\/www.kkh.com.sg\/giving\/Documents\/Rare-Disease-Fund\/index.html. Accessed January 30, 2024."},{"issue":"2","key":"519_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","volume":"19","author":"M Haendel","year":"2020","unstructured":"Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, Hamosh A, Baynam G, Groza T, McMurry J, Dawkins H, Rath A, Thaxton C, Bocci G, Joachimiak MP, K\u00f6hler S, Robinson PN, Mungall C, Oprea TI. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77\u20138. https:\/\/doi.org\/10.1038\/d41573-019-00180-y.","journal-title":"Nat Rev Drug Discov"},{"key":"519_CR4","doi-asserted-by":"publisher","first-page":"1113086","DOI":"10.3389\/fgene.2023.1113086","volume":"14","author":"MP Fu","year":"2023","unstructured":"Fu MP, Merrill SM, Sharma M, Gibson WT, Turvey SE, Kobor MS. Rare diseases of epigenetic origin: challenges and opportunities. Front Genet. 2023;14:1113086. https:\/\/doi.org\/10.3389\/fgene.2023.1113086.","journal-title":"Front Genet"},{"issue":"1","key":"519_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-024-03099-9","volume":"19","author":"QX Ng","year":"2024","unstructured":"Ng QX, Ong C, Yaow CYL, Chan HW, Thumboo J, Wang Y, Koh GCH. Cost-of-illness studies of inherited retinal diseases: a systematic review. Orphanet J Rare Dis. 2024;19(1):93. https:\/\/doi.org\/10.1186\/s13023-024-03099-9.","journal-title":"Orphanet J Rare Dis"},{"key":"519_CR6","doi-asserted-by":"publisher","first-page":"695937","DOI":"10.3389\/fnmol.2021.695937","volume":"14","author":"TL Jensen","year":"2021","unstructured":"Jensen TL, G\u00f8tzsche CR, Woldbye DPD. Current and future prospects for Gene Therapy for Rare Genetic diseases affecting the brain and spinal cord. Front Mol Neurosci. 2021;14:695937. https:\/\/doi.org\/10.3389\/fnmol.2021.695937.","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"519_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/WCO.0000000000001102","volume":"35","author":"C Wurster","year":"2022","unstructured":"Wurster C, Petri S. Progress in spinal muscular atrophy research. Curr Opin Neurol. 2022;35(5):693\u20138. https:\/\/doi.org\/10.1097\/WCO.0000000000001102.","journal-title":"Curr Opin Neurol"},{"key":"519_CR8","unstructured":"Ministry of Health. Singaporeans diagnosed with spinal muscular atrophy and cost of treatment. Ministry of Health. March 22. 2023. https:\/\/www.moh.gov.sg\/news-highlights\/details\/singaporeans-diagnosed-with-spinal-muscular-atrophy-and-cost-of-treatment. Accessed January 15, 2024."},{"key":"519_CR9","unstructured":"Health Sciences Authority. Register of Class 2 Cell, Tissue or Gene Therapy Products. Health Sciences Authority. December 15. 2023. https:\/\/www.hsa.gov.sg\/ctgtp\/ctgtp-register.html. Accessed January 16, 2023."},{"key":"519_CR10","doi-asserted-by":"crossref","unstructured":"Nujiten M. Pricing zolgensma \u2013 the World\u2019s most expensive drug. J Mark Access Health Policy. 2022;10(1).","DOI":"10.1080\/20016689.2021.2022353"},{"key":"519_CR11","unstructured":"Lee L, Baby. in NUH ICU with severe disease, parents hope to raise S$3 million for \u2018world\u2019s most expensive drug\u2019. Today. August 23, 2022. https:\/\/www.todayonline.com\/singapore\/baby-icu-nuh-spinal-muscular-atrophy-severe-disease-fundraiser-expensive-drug-1975686. Accessed January 15, 2023."},{"issue":"4","key":"519_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM, Nusinersen. First Global approval. Drugs. 2017;77(4):473\u20139. https:\/\/doi.org\/10.1007\/s40265-017-0711-7.","journal-title":"Drugs"},{"key":"519_CR13","unstructured":"Department of Health and Aged Care. About the Life Saving Drugs Programme. 2023 Apr 1. https:\/\/www.health.gov.au\/our-work\/life-saving-drugs-program\/about-the-lsdp. Accessed January 16, 2024."},{"issue":"2","key":"519_CR14","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/ijerph16020288","volume":"16","author":"SL Yoo","year":"2019","unstructured":"Yoo SL, Kim DJ, Lee SM, Kang WG, Kim SY, Lee JH, Suh DC. Improving Patient Access to New drugs in South Korea: evaluation of the National Drug Formulary System. Int J Environ Res Public Health. 2019;16(2):288. https:\/\/doi.org\/10.3390\/ijerph16020288.","journal-title":"Int J Environ Res Public Health"},{"key":"519_CR15","unstructured":"National Institute for Health and Care Excellence. The Innovative Medicines Fund Principles. 2022 Jun 6. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2022\/06\/B1686-the-innovate-medicines-fund-principles-june-2022.pdf. Accessed January 16, 2024."},{"issue":"9","key":"519_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2019.0290","volume":"321","author":"S Thomas","year":"2019","unstructured":"Thomas S, Caplan A. The orphan drug act revisited. JAMA. 2019;321(9):833\u20134.","journal-title":"JAMA"},{"key":"519_CR17","unstructured":"World Bank. World Bank Country and Lendind Groups. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups. Accessed January 16, 2024."},{"issue":"1","key":"519_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/jphs.12120","volume":"7","author":"JB Babigumira","year":"2016","unstructured":"Babigumira JB, Jenny AM, Bartlein R, Stergachis A, Garrison LP. Health technology assessment in low-and middle-income countries: a landscape assessment. J Pharm Health Serv Res. 2016;7(1):37\u201342.","journal-title":"J Pharm Health Serv Res"},{"issue":"7","key":"519_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tun\u00e7alp \u00d6, Straus SE. PRISMA Extension for scoping reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"issue":"1","key":"519_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Methodol"},{"key":"519_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1748-5908-5-69","volume":"5","author":"D Levac","year":"2010","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69. https:\/\/doi.org\/10.1186\/1748-5908-5-69.","journal-title":"Implement Sci"},{"issue":"1","key":"519_CR22","first-page":"b92","volume":"1","author":"J Popay","year":"2006","unstructured":"Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, Britten N, Roen K, Duffy S. Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC. Methods Programme Version. 2006;1(1):b92.","journal-title":"Methods Programme Version"},{"key":"519_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/11539190-000000000-00000","volume":"29","author":"CR Blankart","year":"2011","unstructured":"Blankart CR, Stargardt T, Schrey\u00f6gg J. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, fabry disease, hereditary angioedema and chronic myeloid leukaemia. PharmacoEconomics. 2011;29:63\u201382. https:\/\/doi.org\/10.2165\/11539190-000000000-00000.","journal-title":"PharmacoEconomics"},{"key":"519_CR24","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.jval.2020.06.020","volume":"23","author":"AYL Chan","year":"2020","unstructured":"Chan AYL, Chan VKY, Olsson S, Fan M, Jit M, Gong M, Zhang S, Ge M, Pathadka S, Chung CCY, et al. Access and Unmet needs of Orphan drugs in 194 countries and 6 areas: A Global Policy Review with Content Analysis. Value Health. 2020;23:1580\u201391. https:\/\/doi.org\/10.1016\/j.jval.2020.06.020.","journal-title":"Value Health"},{"key":"519_CR25","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.healthpol.2017.09.005","volume":"121","author":"I Degtiar","year":"2017","unstructured":"Degtiar I. A review of international coverage and pricing strategies for personalized medicine and orphan drugs. Health Policy. 2017;121:1240\u20138. https:\/\/doi.org\/10.1016\/j.healthpol.2017.09.005.","journal-title":"Health Policy"},{"key":"519_CR26","doi-asserted-by":"publisher","unstructured":"Gammie T, Lu CY, Ud-Din Babar Z. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS ONE. 2015;10. https:\/\/doi.org\/10.1371\/journal.pone.0140002.","DOI":"10.1371\/journal.pone.0140002"},{"key":"519_CR27","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.drudis.2022.03.002","volume":"27","author":"YJ Huang","year":"2022","unstructured":"Huang YJ, Chao WY, Wang CC, Chang LC. Orphan drug development: the impact of regulatory and reimbursement frameworks. Drug Discovery Today. 2022;27:1724\u201332. https:\/\/doi.org\/10.1016\/j.drudis.2022.03.002.","journal-title":"Drug Discovery Today"},{"key":"519_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/21678707.2021.1913121","volume":"9","author":"JS Bang","year":"2021","unstructured":"Bang JS, Lee JH. The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways. Expert Opin Orphan Drugs. 2021;9:105\u201312. https:\/\/doi.org\/10.1080\/21678707.2021.1913121.","journal-title":"Expert Opin Orphan Drugs"},{"key":"519_CR29","doi-asserted-by":"publisher","unstructured":"Lee SH, Yoo SL, Bang JS, Lee JH. Patient accessibility and budget impact of orphan drugs in South Korea: long-term and real-world data analysis (2007\u20132019). Int J Environ Res Public Health. 2020;17. https:\/\/doi.org\/10.3390\/ijerph17092991.","DOI":"10.3390\/ijerph17092991"},{"key":"519_CR30","doi-asserted-by":"publisher","unstructured":"Lee JH. Pricing and reimbursement pathways of New Orphan drugs in South Korea: a longitudinal comparison. Healthc (Basel Switzerland). 2021;9. https:\/\/doi.org\/10.3390\/healthcare9030296.","DOI":"10.3390\/healthcare9030296"},{"key":"519_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5582\/irdr.2012.v1.1.3","volume":"1","author":"P Song","year":"2012","unstructured":"Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in asia: current status and future perspectives. Intractable Rare Dis Res. 2012;1:3\u20139. https:\/\/doi.org\/10.5582\/irdr.2012.v1.1.3.","journal-title":"Intractable Rare Dis Res"},{"key":"519_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/jphs.12305","volume":"10","author":"A Abbas","year":"2019","unstructured":"Abbas A, Vella Szijj J, Azzopardi LM, Serracino Inglott A. Orphan drug policies in different countries. J Pharm Health Serv Res. 2019;10:295\u2013302. https:\/\/doi.org\/10.1111\/jphs.12305.","journal-title":"J Pharm Health Serv Res"},{"key":"519_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40900-017-0065-z","volume":"3","author":"K Mikami","year":"2017","unstructured":"Mikami K, Sturdy S. Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop. Res Involv Engagem. 2017;3:14. https:\/\/doi.org\/10.1186\/s40900-017-0065-z.","journal-title":"Res Involv Engagem"},{"key":"519_CR34","doi-asserted-by":"publisher","unstructured":"Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014;9. https:\/\/doi.org\/10.1186\/1750-1172-9-62.","DOI":"10.1186\/1750-1172-9-62"},{"key":"519_CR35","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3389\/fphar.2019.01279","volume":"10","author":"E Stawowczyk","year":"2019","unstructured":"Stawowczyk E, Malinowski KP, Kawalec P, Bobinski R, Siwiec J, Panteli D, Eckhardt H, Simoens S, Agusti A, Dooms M, et al. Reimbursement status and recommendations related to Orphan drugs in European Countries. Front Pharmacol. 2019;10:1279. https:\/\/doi.org\/10.3389\/fphar.2019.01279.","journal-title":"Front Pharmacol"},{"key":"519_CR36","doi-asserted-by":"publisher","unstructured":"Annemans L, Ayme S, Le Cam Y, Facey K, Gunther P, Nicod E, Reni M, Roux J-L, Schlander M, Taylor D et al. Recommendations from the European Working Group for Value Assessment and funding processes in Rare diseases (ORPH-VAL). Orphanet J rare Dis 2017, 12, 50, https:\/\/doi.org\/10.1186\/s13023-017-0601-9.","DOI":"10.1186\/s13023-017-0601-9"},{"key":"519_CR37","first-page":"S39","volume":"23","author":"JA Doshi","year":"2017","unstructured":"Doshi JA, Li P, Pettit AR, Dougherty JS, Flint A, Ladage VP. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of too much too soon. Am J Manag Care. 2017;23:S39\u201345.","journal-title":"Am J Manag Care"},{"key":"519_CR38","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/DSS.0000000000002316","volume":"46","author":"K Garland","year":"2020","unstructured":"Garland K, Condon S, Xiong DD, Crowe D, Knackstedt TJ. Mohs surgery for SEER registry-captured melanoma in situ and rare cutaneous tumors: comparing national utilization patterns before and after implementation of the affordable care act (2010) and appropriate use criteria (2012). Dermatol Surg. 2020;46:1021\u20139. https:\/\/doi.org\/10.1097\/DSS.0000000000002316.","journal-title":"Dermatol Surg"},{"key":"519_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11605-022-05496-6","volume":"27","author":"HA Lima","year":"2023","unstructured":"Lima HA, Moazzam Z, Endo Y, Alaimo L, Diaz A, Woldesenbet S, Shaikh C, Munir MM, Azap LE, Yang J, et al. Impact of the Affordable Care Act on Presentation, Treatment, and outcomes of Intrahepatic Cholangiocarcinoma. J Gastrointest Surgery: Official J Soc Surg Aliment Tract. 2023;27:262\u201372. https:\/\/doi.org\/10.1007\/s11605-022-05496-6.","journal-title":"J Gastrointest Surgery: Official J Soc Surg Aliment Tract"},{"key":"519_CR40","doi-asserted-by":"publisher","unstructured":"Margaretos NM, Bawa K, Engmann NJ, Chambers JD. Patients\u2019 access to rare neuromuscular disease therapies varies across US private insurers. Orphanet J rare Dis 2022, 17, 36, https:\/\/doi.org\/10.1186\/s13023-022-02182-3.","DOI":"10.1186\/s13023-022-02182-3"},{"key":"519_CR41","unstructured":"Pharmaceutical Benefits Scheme. AMWG Interim Report to Government - Attachment A. 2008 Jul. https:\/\/www.pbs.gov.au\/info\/general\/working-groups\/amwg\/amwg-interim-report-attachment-a. Accessed January 16, 2024."},{"key":"519_CR42","unstructured":"Canada\u2019s Drug and Health Technology Agency. Drugs for rare diseases: A review of national and international health technology assessment agencies and public payers\u2019 decision-making processes. Canada\u2019s Drug and Health Technology Agency. January 25. 2023. https:\/\/www.cadth.ca\/drugs-rare-diseases-review-national-and-international-health-technology-assessment-agencies-and. Accessed January 16, 2024."},{"issue":"5","key":"519_CR43","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40273-018-0633-6","volume":"36","author":"HW Tuffaha","year":"2018","unstructured":"Tuffaha HW, Scuffham PA. The Australian Managed Entry Scheme: are we getting it right? PharmacoEconomics. 2018;36(5):555\u201365. https:\/\/doi.org\/10.1007\/s40273-018-0633-6.","journal-title":"PharmacoEconomics"},{"key":"519_CR44","doi-asserted-by":"publisher","unstructured":"Lu CY, Lupton C, Rakowsky S, Babar ZU, Ross-Degnan D, Wagner AK. Patient access schemes in Asia-pacific markets: current experience and future potential. J Pharm Policy Pract 20156;8(1):6. https:\/\/doi.org\/10.1186\/s40545-014-0019-x.","DOI":"10.1186\/s40545-014-0019-x"},{"key":"519_CR45","unstructured":"Department of Health and Aged Care. Procedure guidance for medicines funded through the Life Saving Drugs Program (LSDP). 2018 Jul. https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2021\/11\/procedure-guidance-for-medicines-funded-through-the-life-saving-drugs-program-lsdp.pdf. Accessed January 16, 2024."},{"issue":"3","key":"519_CR46","doi-asserted-by":"publisher","first-page":"e0172971","DOI":"10.1371\/journal.pone.0172971","volume":"12","author":"L Chim","year":"2017","unstructured":"Chim L, Salkeld G, Kelly P, Lipworth W, Hughes DA, Stockler MR. Societal perspective on access to publicly subsidised medicines: a cross sectional survey of 3080 adults in Australia. PLoS ONE. 2017;12(3):e0172971. https:\/\/doi.org\/10.1371\/journal.pone.0172971.","journal-title":"PLoS ONE"},{"key":"519_CR47","unstructured":"Department of Health and Aged Care. Ensuring the future sustainability of the Life Saving Drugs Programme (LSDP). 2020 https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2020\/10\/ensuring-the-future-sustainability-of-the-life-saving-drugs-program.pdf. Accessed January 16, 2024."},{"key":"519_CR48","unstructured":"Department of Health and Aged Care. Improving access to medicines \u2013 New medicines added to the Pharmaceutical Benefits Scheme. 2022 May. https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2022\/03\/budget-2022-23-new-medicines-added-to-the-pharmaceutical-benefits-scheme.pdf. Accessed January 16, 2024."},{"key":"519_CR49","unstructured":"Butler M, Department of Health and Aged Care. Life changing gene therapy for babies with spinal muscular atrophy. 2023 Oct 23. https:\/\/www.health.gov.au\/ministers\/the-hon-mark-butler-mp\/media\/life-changing-gene-therapy-for-babies-with-spinal-muscular-atrophy. Accessed January 16, 2024."},{"key":"519_CR50","unstructured":"Pharmaceutical Benefit Scheme. Public Summary Document \u2013 November 2020 PBAC Meeting with May 2021 Addendum. 2021 May. https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2021-05\/files\/onasemnogene-abeparvovec-psd-may-2021.docx. Accessed January 16, 2024."},{"key":"519_CR51","unstructured":"Pharmaceutical Benefit Scheme. Public Summary Document \u2013 November 2020 PBAC Meeting with May 2021 Addendum and September 2021 Addendum. 2021 Sep. https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2021-09\/files\/onasemnogene-abeparvovec-psd-september-2021.docx. Accessed January 16, 2024."},{"key":"519_CR52","unstructured":"Today. Govt looking at more help for children with rare diseases. Today. January 9, 2021. https:\/\/www.todayonline.com\/singapore\/govt-looking-more-help-children-rare-diseases. Accessed January 15, 2024."},{"key":"519_CR53","unstructured":"Ministry of Health. Rare disease fund to provide financial support to Singaporeans with rare diseases. Ministry of Health. July 2. 2019. https:\/\/www.moh.gov.sg\/news-highlights\/details\/rare-disease-fund-to-provide-financial-support-to-singaporeans-with-rare-diseases. Accessed January 15, 2024."},{"key":"519_CR54","unstructured":"National Archives of Singapore Library. Statement by Mr Abdullah Tarmugi. National Archives of Singapore Library. March 10. 1993. https:\/\/www.nas.gov.sg\/archivesonline\/data\/pdfdoc\/at19950310s.pdf. Accessed January 15, 2024."},{"key":"519_CR55","unstructured":"Sin Y. Rare disease fund now covers Pompe disease, a rare inherited neuromuscular disorder. The Straits Times. November 3, 2019. https:\/\/www.straitstimes.com\/singapore\/health\/rare-disease-fund-now-covers-pompe-disease-a-rare-inherited-neuromuscular-disorder. Accessed January 15, 2024."},{"key":"519_CR56","unstructured":"KK Women\u2019s and Children\u2019s Hospital. Rare Disease Fund extends support to another rare disease with $6.7 million gift. KK Women\u2019s and Children\u2019s Hospital. August 19. 2021. https:\/\/www.kkh.com.sg\/news\/giving-philanthropy\/rare-disease-fund-extends-support-to-another-rare-disease-with-67-million-gift. Accessed January 15, 2024."},{"key":"519_CR57","unstructured":"Iau J. 9 Singaporean patients helped by Rare Disease Fund since 2019. The Straits Times. April 11, 2023. https:\/\/www.straitstimes.com\/singapore\/9-patients-or-04-per-cent-of-those-who-suffer-from-rare-diseases-helped-by-fund-since-2019. Accessed January 15, 2024."},{"key":"519_CR58","unstructured":"Medisave MS. Life, and MediFund. Ministry of Health Singapore. https:\/\/www.moh.gov.sg\/cost-financing\/healthcare-schemes-subsidies\/medishield-life. Accessed January 15, 2024."},{"key":"519_CR59","unstructured":"Ministry of Health Singapore. Size annual income and expenditure of rare disease fund. Ministry of Health Singapore. October 4. 2023. https:\/\/www.moh.gov.sg\/news-highlights\/details\/size-annual-income-and-expenditure-of-rare-disease-fund. Accessed January 15, 2024."},{"key":"519_CR60","unstructured":"Ong J. Rare Disease Fund should cover more illnesses, benefit more people: MP Cheryl Chan. Today. August 3, 2021. https:\/\/www.todayonline.com\/singapore\/rare-disease-fund-should-cover-more-illnesses-benefit-more-people-cheryl-chan.html. A Accessed January 15, 2024."},{"key":"519_CR61","unstructured":"Goh YH. More ill children can get help with more donations to Rare Disease Fund says Koh Poh Koon. The Straits Times. August 2, 2021. https:\/\/www.straitstimes.com\/singapore\/politics\/parliament-more-ill-children-can-get-help-with-more-donations-to-rare-diseases. Accessed January 15, 2024."},{"issue":"1","key":"519_CR62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.healthpol.2013.05.007","volume":"113","author":"B Jeon","year":"2013","unstructured":"Jeon B, Kwon S. Effect of private health insurance on health care utilization in a universal public insurance system: a case of South Korea. Health Policy. 2013;113(1):69\u201376.","journal-title":"Health Policy"},{"issue":"3","key":"519_CR63","first-page":"206","volume":"52","author":"YJ Song","year":"2009","unstructured":"Song YJ. The South Korean Healthcare System. Jpn Med Assoc J. 2009;52(3):206\u20139.","journal-title":"Jpn Med Assoc J"},{"key":"519_CR64","unstructured":"Health insurance review and assessment service: national drug formulary. Wonju. 2020 https:\/\/www.hira.or.kr\/bbsDummy.do?pgmid=HIRAA030014050000. Accessed January 15, 2024."},{"issue":"1","key":"519_CR65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/14737167.2020.1758559","volume":"21","author":"S Kim","year":"2021","unstructured":"Kim S, Cho H, Kim J, Lee K, Lee JH. The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):119\u201326. https:\/\/doi.org\/10.1080\/14737167.2020.1758559.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"519_CR66","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13023-019-1032-6","volume":"14","author":"SS Lim","year":"2019","unstructured":"Lim SS, Lee W, Kim YK, Kim J, Park JH, Park BR, Yoon JH. The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011\u20132015. Orphanet J Rare Dis. 2019;14(1):49. https:\/\/doi.org\/10.1186\/s13023-019-1032-6.","journal-title":"Orphanet J Rare Dis"},{"key":"519_CR67","unstructured":"Kim YN. Ultra-expensive SMA drug Zolgensma to get insurance benefits from August. Korea Biomed Rev. July 21, 2022. https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=14205. Accessed January 15, 2024."},{"key":"519_CR68","unstructured":"Chang M. Korea\u2019s 1st gene treatment for SMA Zolgensma gets insurance benefits. Korea Biomed Rev. August 1, 2022. https:\/\/wwwkoreabiomed.com\/news\/articleView.html?idxno=14296. Accessed January 16, 2024."},{"issue":"4","key":"519_CR69","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s13167-010-0050-1","volume":"1","author":"K Grosios","year":"2010","unstructured":"Grosios K, Gahan PB, Burbidge J. Overview of healthcare in the UK. EPMA J. 2010;1(4):529\u201334. https:\/\/doi.org\/10.1007\/s13167-010-0050-1.","journal-title":"EPMA J"},{"issue":"9","key":"519_CR70","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","volume":"26","author":"C McCabe","year":"2008","unstructured":"McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics. 2008;26(9):733\u201344.","journal-title":"PharmacoEconomics"},{"key":"519_CR71","unstructured":"Department of Health and Social Care. England Rare Diseases Action Plan. 2022. 2022 Feb. https:\/\/assets.publishing.service.gov.uk\/media\/62191cf0d3bf7f4f0ec9b6bf\/England-Rare-Diseases-Action-Plan-2022.pdf. Accessed January 16, 2024."},{"key":"519_CR72","unstructured":"National Institute for Health and Care Excellence. Health technology evaluation manual. 2022 Feb 1. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\/changes-to-health-technology-evaluation. Accessed January 16, 2024."},{"key":"519_CR73","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluation topic selection: the manual. 2022 Jan 31. https:\/\/www.nice.org.uk\/process\/pmg37\/chapter\/highly-specialised-technologies. Accessed January 16, 2024."},{"key":"519_CR74","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual, NICE Process and Methods. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/committee-recommendations-2. Accessed January 16, 2024."},{"key":"519_CR75","unstructured":"Centre for Evidence-Based Medicine. Defining value-based healthcare in the NHS. 2019 Apr. https:\/\/www.cebm.net\/wp-content\/uploads\/2019\/04\/Defining-Value-based-healthcare-in-the-NHS-Final4-1.pdf. Accessed January 16, 2024."},{"issue":"10","key":"519_CR76","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/01410768231192476","volume":"116","author":"A Angelis","year":"2023","unstructured":"Angelis A, Aggarwal A, Miners A, Grieve R, Cairns J, Briggs A. The innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a trojan horse for low-value creep? J R Soc Med. 2023;116(10):324\u201330. https:\/\/doi.org\/10.1177\/01410768231192476.","journal-title":"J R Soc Med"},{"key":"519_CR77","unstructured":"Roberts M. Innovative Medicines Fund launched to fast-track drugs. BBC. 2022 Jun 7. https:\/\/www.bbc.com\/news\/health-61709542. Accessed January 16, 2024."},{"issue":"7","key":"519_CR78","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1590\/1413-81232023287.18122022en","volume":"28","author":"R Guimaraes","year":"2023","unstructured":"Guimaraes R. New challenges in health technology assessment (HTA): the case of Zolgensma. cien Saude Colet. 2023;28(7):1881\u20139.","journal-title":"cien Saude Colet"},{"issue":"8","key":"519_CR79","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jval.2012.09.004","volume":"15","author":"A C\u00f4t\u00e9","year":"2012","unstructured":"C\u00f4t\u00e9 A, Keating B. What is wrong with orphan drug policies? Value Health. 2012;15(8):1185\u201391.","journal-title":"Value Health"},{"issue":"10","key":"519_CR80","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1377\/hlthaff.2020.00595","volume":"39","author":"KP Chua","year":"2020","unstructured":"Chua KP, Conti RM. Trends in Orphan drug spending and Out-Of-Pocket spending among US children, 2013\u201318. Health Aff (Millwood). 2020;39(10):1806\u201311.","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"519_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-01943-w","volume":"16","author":"TL Pasquini","year":"2021","unstructured":"Pasquini TL, Goff SL, Whitehill JM. Navigating the US health insurance landscape for children with rare diseases: a qualitative study of parents\u2019 experiences. Orphanet J Rare Dis. 2021;16(1):1\u20134.","journal-title":"Orphanet J Rare Dis"},{"key":"519_CR82","unstructured":"National Organization for Rare Diseases. Protecting Patients in State-Regulated Insurance. https:\/\/rarediseases.org\/policy-issues\/state-regulated-insurance. Accessed January 16, 2024."},{"issue":"11","key":"519_CR83","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1377\/hlthaff.2019.01350","volume":"39","author":"AM Fox","year":"2020","unstructured":"Fox AM, Feng W, Zeitlin J, Howell EA. Trends in State Medicaid Eligibility, Enrollment rules, and benefits. Health Aff (Millwood). 2020;39(11):1909\u201316. https:\/\/doi.org\/10.1377\/hlthaff.2019.01350.","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"519_CR84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21693\/1933-088X-21.2.35","volume":"21","author":"D Drell","year":"2022","unstructured":"Drell D, De Silva A, Lee C. What rare disease patient advocacy groups are doing to mitigate the effects of disparities. Adv Pulm Hypertens. 2022;21(2):35\u201343.","journal-title":"Adv Pulm Hypertens"},{"issue":"3","key":"519_CR85","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jval.2023.12.011","volume":"27","author":"A Wills","year":"2024","unstructured":"Wills A, Mitha A. Financial characteristics of outcomes-based agreements: what do Canadian Public Payers and Pharmaceutical Manufacturers Prefer? Value Health. 2024;27(3):340\u20136. https:\/\/doi.org\/10.1016\/j.jval.2023.12.011.","journal-title":"Value Health"},{"issue":"9","key":"519_CR86","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nbt.3003","volume":"32","author":"TA Brennan","year":"2014","unstructured":"Brennan TA, Wilson JM. The special case of gene therapy pricing. Nat Biotechnol. 2014;32(9):874\u20136. https:\/\/doi.org\/10.1038\/nbt.3003.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"519_CR87","doi-asserted-by":"publisher","first-page":"1715536","DOI":"10.1080\/20016689.2020.1715536","volume":"8","author":"J J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy. 2020;8(1):1715536. https:\/\/doi.org\/10.1080\/20016689.2020.1715536.","journal-title":"J Mark Access Health Policy"},{"key":"519_CR88","unstructured":"Alex Watt. Risk-sharing agreements are growing at a rate of 24%. Pharmaceutical Technology. February 10. 2023. https:\/\/www.pharmaceutical-technology.com\/pricing-and-market-access\/risk-sharing-agreements. Accessed January 30, 2024."},{"key":"519_CR89","doi-asserted-by":"publisher","first-page":"594446","DOI":"10.3389\/fphar.2020.594446","volume":"11","author":"S Michelsen","year":"2020","unstructured":"Michelsen S, Nachi S, Van Dyck W, Simoens S, Huys I. Barriers and opportunities for implementation of outcome-based spread payments for High-Cost, one-shot curative therapies. Front Pharmacol. 2020;11:594446. https:\/\/doi.org\/10.3389\/fphar.2020.594446.","journal-title":"Front Pharmacol"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-024-00519-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-024-00519-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-024-00519-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T21:04:48Z","timestamp":1718831088000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/s13561-024-00519-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1186\/s13561-024-00519-1","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No patients or participants were directly involved in this study as it was a review of published literature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}